Systemic treatment of advanced differentiated and medullary thyroid cancer Overview and practical aspects

被引:0
|
作者
Kreissl, M. C. [1 ,2 ]
Fassnacht, M. [3 ]
Mueller, S. P. [4 ]
机构
[1] Cent Hosp Augsburg, Dept Nucl Med, Augsburg, Germany
[2] Univ Wurzburg, Dept Nucl Med, Univ Hosp, Wurzburg, Germany
[3] Univ Wurzburg, Div Endocrinol, Univ Hosp, Dept Internal Med 1, Wurzburg, Germany
[4] Univ Hosp Essen, Dept Nucl Med, Essen, Germany
来源
NUKLEARMEDIZIN-NUCLEAR MEDICINE | 2015年 / 54卷 / 03期
关键词
Medullary thyroid carcinoma; differentiated thyroid cancer; systemic therapy; tyrosine kinase inhibitor; TYROSINE KINASE INHIBITOR; PHASE-II TRIAL; PROGNOSTIC VALUE; BRAF(V600E) MUTATION; EMISSION-TOMOGRAPHY; DISTANT METASTASES; TUMOR PROGRESSION; POTENT ANTITUMOR; CARCINOMA; SORAFENIB;
D O I
暂无
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
In the last few years, three new drugs for targeted systemic therapies have been approved for advanced and progressive thyroid cancer, namely vandetanib and cabozantinib for medullary and sorafenib for radioiodine refractory differentiated thyroid cancer. Patient selection by an interdisciplinary team and education of patients by the treating physicians play a major role when such a treatment is considered and initiated. Only patients with significant tumor burden and/or symptomatic disease or progression, which cannot be controlled by local therapies, should be treated. In order to preserve quality of life, the management of adverse effects is of utmost importance. Due to the mechanism of action of these tyrosine kinase inhibitors, the reliability of serum tumour markers, calcitonin and thyroglobulin, is limited for the assessment of response and follow-up, therefore morphological and metabolic imaging is of great importance. Minor or localized progression should not automatically trigger the termination of treatment or change of drug. In the near future, it is expected that additional drugs become available.
引用
收藏
页码:88 / 93
页数:6
相关论文
共 50 条
  • [1] Targeted Treatment of Differentiated and Medullary Thyroid Cancer
    Bales, Shannon R.
    Chopra, Inder J.
    JOURNAL OF THYROID RESEARCH, 2011, 2011
  • [2] Treatment of advanced medullary thyroid cancer
    Smit J.
    Thyroid Research, 6 (Suppl 1)
  • [3] New aspects of systemic therapy of medullary thyroid cancer
    Fassnacht, M.
    Schmidmaier, R.
    Kroiss, M.
    Kreissl, M. C.
    ONKOLOGE, 2013, 19 (03): : 209 - +
  • [4] Systemic treatment of advanced, metastatic, medullary thyroid carcinoma
    Matrone, Antonio
    Gambale, Carla
    Prete, Alessandro
    Cappagli, Virginia
    Lorusso, Loredana
    Bottici, Valeria
    Elisei, Rossella
    JOURNAL OF CANCER METASTASIS AND TREATMENT, 2021, 7
  • [5] Axitinib treatment in advanced RAI-resistant differentiated thyroid cancer (DTC) and refractory medullary thyroid cancer (MTC)
    Capdevila, Jaume
    Manuel Trigo, Jose
    Aller, Javier
    Luis Manzano, Jose
    Garcia Adrin, Silvia
    Zafon Llopis, Carles
    Reig, Oscar
    Bohn, Uriel
    Ramon y Cajal, Teresa
    Duran-Poveda, Manuel
    Gonzalez Astorga, Beatriz
    Lopez-Alfonso, Ana
    Medina Martinez, Javier
    Porras, Ignacio
    Jose Reina, Juan
    Palacios, Nuria
    Grande, Enrique
    Cillan, Elena
    Matos, Ignacio
    Jose Grau, Juan
    EUROPEAN JOURNAL OF ENDOCRINOLOGY, 2017, 177 (04) : 309 - 317
  • [6] Axitinib treatment in advanced RAI-resistant differentiated thyroid cancer (DTC) and refractory medullary thyroid cancer (MTC)
    Capdevila, Jaume
    Trigo Perez, Jose Manuel
    Aller, Javier
    Luis Manzano, Jose
    Garcia Adrian, Silvia
    Zafon, Carles
    Reig, Oscar
    Bohn, Uriel
    Cillan, Elena
    Duran, Manuel
    Gonzalez Astorga, Beatriz
    Lopez, Ana
    Javier, Medina
    Porras, Ignacio
    Reina, Juan J.
    Palacios, Nuria
    Grande, Enrique
    Grau, Juan J.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [7] Cabozantinib for the Treatment of Advanced Medullary Thyroid Cancer
    Nagilla, Madhavi
    Brown, Rebecca L.
    Cohen, Ezra E. W.
    ADVANCES IN THERAPY, 2012, 29 (11) : 925 - 934
  • [8] Cabozantinib for the Treatment of Advanced Medullary Thyroid Cancer
    Madhavi Nagilla
    Rebecca L. Brown
    Ezra E. W. Cohen
    Advances in Therapy, 2012, 29 : 925 - 934
  • [9] Safety of denosumab in patients with refractory differentiated thyroid cancer and advanced medullary thyroid cancer.
    Wassermann, Johanna
    Mathy, Elise
    Lescaille, Geraldine
    Slim, Marine
    Buffet, Camille
    Saie, Clotilde
    Braik-Djellas, Yasmin
    Simon, Jean-Marc
    Menegaux, Fabrice
    Tresallet, Christophe
    Chami, Linda
    Lussey-Lepoutre, Charlotte
    Herve, Genevieve
    Bernier, Marie-Odile
    Spano, Jean-Philippe
    Leenhardt, Laurence
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [10] Systemic treatment and management approaches for medullary thyroid cancer
    Ernani, Vinicius
    Kumar, Mukesh
    Chen, Amy Y.
    Owonikoko, Taofeek K.
    CANCER TREATMENT REVIEWS, 2016, 50 : 89 - 98